Impact of Increased Single-Inhaler Triple Therapy Use in Appropriate Patients on Chronic Obstructive Pulmonary Disease Exacerbations, Mortality, and Medical Costs: PROMETHEUS Spain
Based on our simulation, increased use of SITT in the Spanish COPD population, consistent with the most recent 2025 GOLD report recommendations, could reduce mortality and exacerbations and their corresponding medical costs. Increasing SITT utilization in patients with COPD may constitute a long-term strategy with relevant clinical and economic benefits.
Authors
- Melissa Caplen
- Jennifer Carioto
- Jorge Mestre-Ferrándiz (ORCID: https://orcid.org/0000-0003-0529-1321)
- Joaquín Sánchez-Covisa (ORCID: https://orcid.org/0000-0002-6407-3669)
- John Bell (ORCID: https://orcid.org/0000-0001-9307-1235)
- Bruce Pyenson (ORCID: https://orcid.org/0000-0003-0416-9391)
- Prachi Bhatt
- Marta Marín‐Oto (ORCID: https://orcid.org/0000-0003-0777-3850)
- C. García
- Néstor Martínez-Martínez
Institutions
- AstraZeneca (France) (FR)
- AstraZeneca (Switzerland) (CH)
- Hospital Clínico Universitario Lozano Blesa (ES)
- AstraZeneca (Poland) (PL)
- AstraZeneca (Spain) (ES)
- Universidad Carlos III de Madrid (ES)
- Milliman (United States) (US)
Publication Details
- Journal
- Respiration
- Published
- 2025-11-21
- DOI
- https://doi.org/10.1159/000549626
- Citations
- 1
- Primary Topic
- Inhalation and Respiratory Drug Delivery
- Type
- article
- Field-Weighted Citation Impact
- 1.52
Funders
- AstraZeneca